WO2003066104A2 - Composition pharmaceutique ameliorant le transfert de gene in vivo - Google Patents

Composition pharmaceutique ameliorant le transfert de gene in vivo Download PDF

Info

Publication number
WO2003066104A2
WO2003066104A2 PCT/FR2003/000407 FR0300407W WO03066104A2 WO 2003066104 A2 WO2003066104 A2 WO 2003066104A2 FR 0300407 W FR0300407 W FR 0300407W WO 03066104 A2 WO03066104 A2 WO 03066104A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
nucleic acid
pharmaceutical composition
compound
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/000407
Other languages
English (en)
French (fr)
Other versions
WO2003066104A3 (fr
Inventor
Bruno Pitard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CA2473212A priority Critical patent/CA2473212C/fr
Priority to JP2003565527A priority patent/JP4613011B2/ja
Priority to EP03718854A priority patent/EP1471944B1/fr
Priority to DE60305443T priority patent/DE60305443T2/de
Priority to AU2003222896A priority patent/AU2003222896A1/en
Priority to US10/502,973 priority patent/US7709452B2/en
Publication of WO2003066104A2 publication Critical patent/WO2003066104A2/fr
Publication of WO2003066104A3 publication Critical patent/WO2003066104A3/fr
Anticipated expiration legal-status Critical
Priority to US12/659,618 priority patent/US8367631B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • GFP Green-Fluorescent Protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/FR2003/000407 2002-02-08 2003-02-07 Composition pharmaceutique ameliorant le transfert de gene in vivo Ceased WO2003066104A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2473212A CA2473212C (fr) 2002-02-08 2003-02-07 Composition pharmaceutique ameliorant le transfert de gene in vivo
JP2003565527A JP4613011B2 (ja) 2002-02-08 2003-02-07 ｉｎｖｉｖｏ遺伝子伝達を改善する医薬組成物
EP03718854A EP1471944B1 (fr) 2002-02-08 2003-02-07 Composition pharmaceutique ameliorant le transfert de gene in vivo
DE60305443T DE60305443T2 (de) 2002-02-08 2003-02-07 Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung
AU2003222896A AU2003222896A1 (en) 2002-02-08 2003-02-07 Pharmaceutical composition which improves in vivo gene transfer
US10/502,973 US7709452B2 (en) 2002-02-08 2003-02-07 Pharmaceutical composition which improves in vivo gene transfer
US12/659,618 US8367631B2 (en) 2002-02-08 2010-03-15 Pharmaceutical composition which improves in vivo gene transfer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/01584 2002-02-08
FR0201584A FR2835749B1 (fr) 2002-02-08 2002-02-08 Composition pharmaceutique ameliorant le transfert de gene in vivo

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10502973 A-371-Of-International 2003-02-07
US12/659,618 Continuation US8367631B2 (en) 2002-02-08 2010-03-15 Pharmaceutical composition which improves in vivo gene transfer

Publications (2)

Publication Number Publication Date
WO2003066104A2 true WO2003066104A2 (fr) 2003-08-14
WO2003066104A3 WO2003066104A3 (fr) 2004-03-25

Family

ID=27620039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/000407 Ceased WO2003066104A2 (fr) 2002-02-08 2003-02-07 Composition pharmaceutique ameliorant le transfert de gene in vivo

Country Status (10)

Country Link
US (2) US7709452B2 (cg-RX-API-DMAC7.html)
EP (1) EP1471944B1 (cg-RX-API-DMAC7.html)
JP (1) JP4613011B2 (cg-RX-API-DMAC7.html)
AT (1) ATE326986T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003222896A1 (cg-RX-API-DMAC7.html)
CA (1) CA2473212C (cg-RX-API-DMAC7.html)
DE (1) DE60305443T2 (cg-RX-API-DMAC7.html)
ES (1) ES2265569T3 (cg-RX-API-DMAC7.html)
FR (1) FR2835749B1 (cg-RX-API-DMAC7.html)
WO (1) WO2003066104A2 (cg-RX-API-DMAC7.html)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868953A1 (fr) * 2004-04-16 2005-10-21 Inst Nat Sante Rech Med Composition pour le transfert intracellulaire d'un acide nucleique.
DE102006051623A1 (de) 2006-11-02 2008-07-31 Horn, Peter A. Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers
WO2013128424A1 (en) 2012-03-02 2013-09-06 Institut National De La Sante Et De La Recherche Medicale Vaccine for prophylaxis or treatment of an allergen-driven and/or a chronic airways disease
WO2013186394A1 (en) 2012-06-15 2013-12-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides for use in the prophylactic treatment of allergic asthma
WO2015151048A1 (en) * 2014-04-01 2015-10-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Capped and uncapped rna molecules and block copolymers for intracellular delivery of rna
WO2019170584A1 (en) 2018-03-05 2019-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and composition for the treatment of allergic asthma
WO2022229227A1 (en) 2021-04-28 2022-11-03 Ospedale San Raffaele S.R.L. Compositions for improving the transduction of cells by viral vectors
WO2023209225A1 (en) 2022-04-29 2023-11-02 Ospedale San Raffaele S.R.L. Gene therapy

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034123A2 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
WO2010026537A1 (en) 2008-09-05 2010-03-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel multimodular assembly useful for intracellular delivery
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013106558A1 (en) 2012-01-10 2013-07-18 Merial Limited Lipid based adjuvants for dna - plasmid vaccines
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3225246A1 (en) 2016-03-31 2017-10-04 Klinikum der Universität München Synthetic compound for improving efficiency of transfection
US20220184191A1 (en) * 2019-03-11 2022-06-16 Evaxion Biotech A/S Nucleic acid vaccination using neo-epitope encoding constructs
EP4704856A1 (en) 2023-03-30 2026-03-11 Vivadju Pvax14 nucleic acid formulated with nano-vehicle in combination with all-trans retinoic acid (atra) for activating immune pathways
WO2024200831A1 (en) 2023-03-30 2024-10-03 Vivadju Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer
WO2025129128A1 (en) 2023-12-15 2025-06-19 Vivasor, Inc. Compositions and methods for non-viral delivery of therapeutic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US6221959B1 (en) * 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
CA2315256A1 (en) * 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
GB9904627D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
AU4898699A (en) 1999-07-16 2001-02-05 Reatech Phosphor addition in gasification
AU6389000A (en) * 1999-07-28 2001-02-19 Valentis, Inc. Sonoporation of tumors
WO2001060415A1 (en) * 2000-02-18 2001-08-23 The Immune Response Corporation Methods and compositions for gene delivery
AU2001241958A1 (en) * 2000-03-03 2001-09-17 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
CA2426582A1 (en) 2000-10-20 2002-08-08 Valentis, Inc. Gene delivery formulations and methods for treatment of ischemic conditions

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868953A1 (fr) * 2004-04-16 2005-10-21 Inst Nat Sante Rech Med Composition pour le transfert intracellulaire d'un acide nucleique.
WO2005099763A3 (fr) * 2004-04-16 2006-04-13 Inst Nat Sante Rech Med Composition pour le transfert intracellulaire d’un acide nucleique
DE102006051623A1 (de) 2006-11-02 2008-07-31 Horn, Peter A. Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers
WO2013128424A1 (en) 2012-03-02 2013-09-06 Institut National De La Sante Et De La Recherche Medicale Vaccine for prophylaxis or treatment of an allergen-driven and/or a chronic airways disease
WO2013186394A1 (en) 2012-06-15 2013-12-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides for use in the prophylactic treatment of allergic asthma
WO2015151048A1 (en) * 2014-04-01 2015-10-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Capped and uncapped rna molecules and block copolymers for intracellular delivery of rna
US11179478B2 (en) 2014-04-01 2021-11-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Capped and uncapped RNA molecules and block copolymers for intracellular delivery of RNA
WO2019170584A1 (en) 2018-03-05 2019-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and composition for the treatment of allergic asthma
WO2022229227A1 (en) 2021-04-28 2022-11-03 Ospedale San Raffaele S.R.L. Compositions for improving the transduction of cells by viral vectors
WO2023209225A1 (en) 2022-04-29 2023-11-02 Ospedale San Raffaele S.R.L. Gene therapy

Also Published As

Publication number Publication date
EP1471944B1 (fr) 2006-05-24
EP1471944A2 (fr) 2004-11-03
FR2835749B1 (fr) 2006-04-14
US20100179212A1 (en) 2010-07-15
JP2005522433A (ja) 2005-07-28
AU2003222896A1 (en) 2003-09-02
CA2473212A1 (fr) 2003-08-14
WO2003066104A3 (fr) 2004-03-25
US7709452B2 (en) 2010-05-04
US20050152870A1 (en) 2005-07-14
ES2265569T3 (es) 2007-02-16
ATE326986T1 (de) 2006-06-15
CA2473212C (fr) 2013-04-23
FR2835749A1 (fr) 2003-08-15
JP4613011B2 (ja) 2011-01-12
DE60305443T2 (de) 2007-05-10
DE60305443D1 (de) 2006-06-29
US8367631B2 (en) 2013-02-05
AU2003222896A8 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
EP1471944B1 (fr) Composition pharmaceutique ameliorant le transfert de gene in vivo
JP5095708B2 (ja) 核酸様化合物の送達
EP0809705B1 (fr) Compositions contenant des acides nucleiques, preparation et utilisation
Ewe et al. Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo
CA2194797C (fr) Composition contenant des acides nucleiques, preparation et utilisations
EP0738328B1 (fr) Composition contenant des acides nucleiques, preparation et utilisations
US20210346306A1 (en) Delivery of dna
EP1007097B1 (fr) Formulation de particules agent(s) de transfection cationique(s)/acides nucleiques stabilisees
EP0854930A1 (fr) Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
WO2023233159A1 (en) Therapeutic compounds and compositions
JP4450656B2 (ja) リポソームからなる遺伝子導入用キャリア
CN117460537A (zh) 核酸递送
CA2272637A1 (fr) Composition transfectante utile en therapie genique associant a un virus recombinant incorporant un acide nucleique exogene, un agent de transfection non viral et non plasmidique
WO2005099763A2 (fr) Composition pour le transfert intracellulaire d’un acide nucleique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003718854

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2473212

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003565527

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003718854

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10502973

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2003718854

Country of ref document: EP